Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 28, 2025
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
European Urology|October 9, 2018
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene DefectsPedro Isaacsson Velho, Fahad Qazi, Sayeedul Hassan, et al.
The Prostate|August 10, 2023
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancerJohn T Isaacs, Susan L Dalrymple, Lizamma Antony, et al.
Science Translational Medicine|January 9, 2015
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical studyMichael T Schweizer, Emmanuel S Antonarakis, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Stem Cells Translational Medicine|March 30, 2019
In ReplyW Nathaniel Brennen, Michael T Schweizer, Hao Wang, et al.
Stem Cells Translational Medicine|February 9, 2019
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate CancerMichael T Schweizer, Hao Wang, Trinity J Bivalacqua, et al.
European Urology|June 10, 2019
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate CancerPedro Isaacsson Velho, Wei Fu, Hao Wang, et al.
JCO Precision Oncology|October 26, 2019
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomyPedro Isaacsson Velho, David Lim, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 28, 2025
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
European Urology|October 9, 2018
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene DefectsPedro Isaacsson Velho, Fahad Qazi, Sayeedul Hassan, et al.
The Prostate|August 10, 2023
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancerJohn T Isaacs, Susan L Dalrymple, Lizamma Antony, et al.
Science Translational Medicine|January 9, 2015
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical studyMichael T Schweizer, Emmanuel S Antonarakis, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Stem Cells Translational Medicine|March 30, 2019
In ReplyW Nathaniel Brennen, Michael T Schweizer, Hao Wang, et al.
Stem Cells Translational Medicine|February 9, 2019
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate CancerMichael T Schweizer, Hao Wang, Trinity J Bivalacqua, et al.
European Urology|June 10, 2019
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate CancerPedro Isaacsson Velho, Wei Fu, Hao Wang, et al.
JCO Precision Oncology|October 26, 2019
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomyPedro Isaacsson Velho, David Lim, Hao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Pageof 16